Literature DB >> 18508679

Tumor microenvironment and angiogenesis.

Pia Nyberg1, Tuula Salo, Raghu Kalluri.   

Abstract

The tumor microenvironment is a mixture of extracellular matrix molecules, tumor cells, endothelial cells, fibroblasts and immune cells. Tumor growth and metastasis formation are dependent on the growth of blood vessels into the tumor mass. The tumor microenvironment contributes to this pathological angiogenic process. The extracellular matrix and basement membranes are a source for endogenous angiogenesis inhibitors, such as endostatin. On the other hand, many extracellular matrix molecules can promote angiogenesis by stabilizing blood vessels and sequestering pro-angiogenic growth factors. The majority of stromal cells in carcinomas are fibroblasts. Carcinoma-associated fibroblasts show a distinct phenotype from normal fibroblasts. The mechanisms how the tumor-associated fibroblasts regulate angiogenesis are not fully known, but they are suggested to be an important source for growth factors and cytokines recruiting endothelial cells. The immune cells, particularly macrophages and neutrophils are another source for angiogenesis-regulating chemokines, growth factors and proteases. Taken together, the tumor microenvironment is a complex unorganized tissue of various cell types and extracellular matrix that can regulate the pathological angiogenic switch.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508679     DOI: 10.2741/3173

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  66 in total

1.  Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.

Authors:  Yanping Ding; Nan Song; Yongzhang Luo
Journal:  Cancer Microenviron       Date:  2012-04-20

Review 2.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

Review 3.  Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function.

Authors:  Helge Wiig; Doruk Keskin; Raghu Kalluri
Journal:  Matrix Biol       Date:  2010-08-18       Impact factor: 11.583

Review 4.  Small-molecule inhibitors of the Myc oncoprotein.

Authors:  Steven Fletcher; Edward V Prochownik
Journal:  Biochim Biophys Acta       Date:  2014-03-19

Review 5.  Screening the cellular microenvironment: a role for microfluidics.

Authors:  Jay W Warrick; William L Murphy; David J Beebe
Journal:  IEEE Rev Biomed Eng       Date:  2008-11-05

6.  Maclurin suppresses migration and invasion of human non-small-cell lung cancer cells via anti-oxidative activity and inhibition of the Src/FAK-ERK-β-catenin pathway.

Authors:  Min Jung Ku; Ji Hyun Kim; Jongsung Lee; Jae Youl Cho; Taehoon Chun; Sang Yeol Lee
Journal:  Mol Cell Biochem       Date:  2015-01-29       Impact factor: 3.396

7.  Immunotherapy of tumor with vaccine based on basic fibroblast growth factor-activated fibroblasts.

Authors:  Xiuying Li; Yongsheng Wang; Yuwei Zhao; Hengxiu Yang; Aiping Tong; Chengjian Zhao; Huashan Shi; Yang Li; Zhenlin Wang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-10       Impact factor: 4.553

8.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

9.  Anti-tumor therapy with macroencapsulated endostatin producer cells.

Authors:  Danielle B Rodrigues; Roger Chammas; Natália V Malavasi; Patrícia L N da Costa; Rosa M Chura-Chambi; Keli N Balduino; Ligia Morganti
Journal:  BMC Biotechnol       Date:  2010-03-02       Impact factor: 2.563

10.  Angiogenesis and vascular network of teratocarcinoma from embryonic stem cell transplant into seminiferous tubules.

Authors:  U Silván; J Arlucea; R Andrade; A Díez-Torre; M Silió; M A Konerding; J Aréchaga
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.